<DOC>
	<DOCNO>NCT00287508</DOCNO>
	<brief_summary>To collect clinical outcome device performance data FDA 510 ( k ) -cleared Emboshield® BareWire™ Rapid Exchange Embolic Protection System FDA-approved Xact® Rapid Exchange Carotid Stent System use commercial use condition broad group physician enter study differ carotid artery stenting experience .</brief_summary>
	<brief_title>Emboshield® Xact® Post Approval Carotid Stent Trial ( The EXACT Study )</brief_title>
	<detailed_description>This multi-center , observational , single arm , post-approval study enrol follow study population : - Subjects neurological symptom &gt; = 50 % stenosis common internal carotid artery ultrasound angiogram ( visual estimate ) , - Subjects without neurological symptom &gt; = 80 % stenosis common internal carotid artery ultrasound angiogram ( visual estimate ) - The endpoint 1500 subject enrol 30-day composite death , stroke myocardial infarction ( MI ) . - For 500 subject 12 month follow-up , endpoint composite stroke , death MI 30 day ipsilateral stroke 12 month ( 31-365 day ) .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<criteria>Subjects agree participate study sign IRB approve informed consent form . Subjects willing Emboshield and/or Xact inserted vasculature . There exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Carotid stenting</keyword>
	<keyword>Carotid endarterectomy</keyword>
	<keyword>Carotid artery disease severe narrowing artery</keyword>
	<keyword>Stroke prevention</keyword>
	<keyword>cerebral infarction</keyword>
</DOC>